Nexalin Targets Q2 2026 Enrollment for Pivotal Insomnia Device Trial
Event summary
- Nexalin Technology plans to begin enrollment for its pivotal clinical trial of the HALO™ Clarity device in Q2 2026.
- The 160-participant trial is designed to support a De Novo Classification Request to the FDA.
- Lindus Health will manage full-scope trial execution, including regulatory submissions and data oversight.
- The global sleep tech devices market is projected to reach $153.7 billion by 2035, per Precedence Research.
The big picture
Nexalin’s advancement toward a pivotal trial for its insomnia treatment device comes as the sleep tech market expands rapidly. The company aims to differentiate its non-invasive neurostimulation approach in a sector dominated by pharmaceutical solutions, potentially tapping into a $153.7 billion market by 2035. Success in this trial could position Nexalin as a key player in mental health treatment, but regulatory and competitive hurdles remain significant.
What we're watching
- Regulatory Pathway
- Whether the De Novo classification request will succeed in establishing HALO™ Clarity as a new product category.
- Trial Execution
- The pace at which Nexalin can enroll participants and complete the trial, given the collaboration with Lindus Health.
- Market Potential
- How the HALO™ Clarity device will compete in the rapidly growing sleep tech market, particularly against existing pharmacologic treatments.
Related topics